Sphingosylphosphorylcholine (SPC), a sphingolipid metabolite, has recently
been reported to stimulate wound healing in an animal model. To clarify the
mechanism of SPC on the healing process, we examined the effect of SPC on
wound contraction using an in vitro model. A mixture of human dermal fibrob
lasts and porcine type I collagen in a serum-free medium was gelled, and th
en separated from the well after a 12-h incubation. Various reagents were a
pplied to the medium, and its contractile activity was analysed by measurin
g the amount of contracted surface area. Among the sphingolipid metabolites
, SPC and sphingosine-1-phosphate, but not sphingosine, C-2-ceramide and C-
6-ceramide, stimulated collagen gel contraction. Maximal gel contraction, o
bserved at 10 mu mol L-1 of SPC, occurred as early as 1 h after the treatme
nt and persisted for more than 48 h. The effect of SPC was not inhibited by
pretreatment with antitransforming growth factor-beta or antiplatelet-deri
ved growth factor-BB antibodies. Among the various signal transduction inhi
bitors, pertussis toxin, staurosporine and H7 were found to inhibit the act
ion of SPC, whereas genistein and tyrphostin A47 were not, suggesting that
fibroblast contraction induced by SPC is mediated by a trimeric guanosine t
riphosphate-binding protein (G protein)-coupled receptor and protein kinase
. Our findings imply that the effect of SPC as a healing stimulant might be
due in part to stimulation of fibroblast contraction in granulation tissue
.